PH009-1

Phase I: Primary purpose: to evaluate the safety and tolerability of PH009-1 and determine the maximum tolerated dose (MTD) or RP2D; Secondary purpose: to evaluate the pharmacokinetic (PK) characteristics of PH009-1 after single and multiple oral administration; to evaluate the preliminary anti-tumor activity of PH009-1 after oral administration, etc.; Phase IIa: Primary purpose: to evaluate the preliminary anti-tumor activity of PH009-1 after oral administration at a selected dose and the safety of PH009-1 after oral administration at a selected dose; Secondary purpose: to further evaluate the anti-tumor activity of PH009-1 after oral administration at a selected dose and the PK characteristics of PH009-1 after oral administration at a selected dose, etc.;